AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is wrapping up the refinancing of its existing debt facility with Hercules and affiliates: one with a $20 million …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced updates on clinical development for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2017 and provided a business update.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and EUSA Pharma announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced the successful completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, …
